NAS:ICPT (USA) Also trade in: Germany

Intercept Pharmaceuticals Inc

$ 83.27 0.16 (0.19%)
Volume: 466,100 Avg Vol (1m): 811,124
Market Cap $: 2.71 Bil Enterprise Value $: 2.73 Bil
P/E (TTM): 0.00 P/B: 0.00
Earnings Power Value -1457.03
Net Current Asset Value -3.04
Tangible Book -1.85
Projected FCF -104.99
Median P/S Value 2159.19
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 3/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 0.94
Cash-To-Debt ranked lower than
75.97% of 1078 companies
in the Biotechnology industry.
Industry Max: 20856.43, Med: 64.02, Min: 0.01
ICPT: 0.94
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 0.91, Med: 10000, Max: 10000
Current: 0.94
0.91
10000
Equity-to-Asset -0.13
Equity-to-Asset ranked lower than
86.50% of 763 companies
in the Biotechnology industry.
Industry Max: 3.47, Med: 0.69, Min: -9.46
ICPT: -0.13
Ranked among companies with meaningful Equity-to-Asset only.
Equity-to-Asset range over the past 10 years
Min: -1.08, Med: 0.51, Max: 0.96
Current: -0.13
-1.08
0.96
Debt-to-Equity -6.82
Debt-to-Equity ranked lower than
95.00% of 500 companies
in the Biotechnology industry.
Industry Max: 35.66, Med: 0.28, Min: 0.01
ICPT: -6.82
Ranked among companies with meaningful Debt-to-Equity only.
Debt-to-Equity range over the past 10 years
Min: -6.88, Med: 1.74, Max: 21.71
Current: -6.82
-6.88
21.71
Debt-to-EBITDA -1.33
Debt-to-EBITDA ranked lower than
100.00% of 196 companies
in the Biotechnology industry.
Industry Max: 1208.58, Med: 2.04, Min: 0.01
ICPT: -1.33
Ranked among companies with meaningful Debt-to-EBITDA only.
Debt-to-EBITDA range over the past 10 years
Min: -1.35, Med: -0.98, Max: -0.01
Current: -1.33
-1.35
-0.01
Piotroski F-Score 2
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -3.73
DISTRESS
GREY
SAFE
Beneish M-Score -2.62
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC 0%
WACC 10.5%

Profitability & Growth : 5/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % -149.92
Operating Margin ranked lower than
56.06% of 792 companies
in the Biotechnology industry.
Industry Max: 46829238.82, Med: -113.97, Min: -1969600
ICPT: -149.92
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: -8237.1, Med: -1193.29, Max: -149.92
Current: -149.92
-8237.1
-149.92
Net Margin % -162.13
Net Margin ranked lower than
57.20% of 792 companies
in the Biotechnology industry.
Industry Max: 49899604.52, Med: -111.91, Min: -2150400
ICPT: -162.13
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: -16258.67, Med: -1719.41, Max: -162.13
Current: -162.13
-16258.67
-162.13
ROE % -1030.61
ROE ranked lower than
95.35% of 989 companies
in the Biotechnology industry.
Industry Max: 326.78, Med: -42.82, Min: -100794.12
ICPT: -1030.61
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: -1741.42, Med: -146.09, Max: -54.36
Current: -1030.61
-1741.42
-54.36
ROA % -63.51
ROA ranked lower than
71.40% of 1084 companies
in the Biotechnology industry.
Industry Max: 224.74, Med: -34.77, Min: -3751.92
ICPT: -63.51
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: -140.05, Med: -60.72, Max: -49.77
Current: -63.51
-140.05
-49.77
ROC (Joel Greenblatt) % -2575.81
ROC (Joel Greenblatt) ranked lower than
68.24% of 1036 companies
in the Biotechnology industry.
Industry Max: 641137.84, Med: -521.46, Min: -3427023.81
ICPT: -2575.81
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: -8893.89, Med: -5590.69, Max: -2096.03
Current: -2575.81
-8893.89
-2096.03
3-Year Total Revenue Growth Rate 301.30
3-Year Revenue Growth Rate ranked higher than
99.08% of 651 companies
in the Biotechnology industry.
Industry Max: 906.3, Med: 1.1, Min: -100
ICPT: 278
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
3-Year Revenue Growth Rate range over the past 10 years
Min: 0, Med: 45.5, Max: 296.3
Current: 278
0
296.3
3-Year Total EBITDA Growth Rate -6.80
3-Year EBITDA Growth Rate ranked lower than
53.49% of 802 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 4.6, Min: -2038.5
ICPT: -0.5
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
3-Year EBITDA Growth Rate range over the past 10 years
Min: -62.2, Med: -23.8, Max: 7.7
Current: -0.5
-62.2
7.7
3-Year EPS w/o NRI Growth Rate -4.30
3-Year EPS w/o NRI Growth Rate ranked lower than
58.06% of 763 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 5.7, Min: -2103.4
ICPT: -4.3
Ranked among companies with meaningful 3-Year EPS w/o NRI Growth Rate only.
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: -125.4, Med: -6.7, Max: 11.4
Current: -4.3
-125.4
11.4

» ICPT's 30-Y Financials

Financials (Next Earnings Date: 2019-08-02)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:ICPT

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 325412    SIC : 2834
Compare TSE:4974 XBRU:TUB XKRX:086900 XSWX:IDIA SHSE:600201 NYSE:EBS NYSE:BHVN NAS:LGND SHSE:603233 NAS:PTLA XMAD:ALM NAS:RETA NAS:INSM HKSE:00570 NAS:HALO SZSE:300009 XSWX:GALE NAS:DNLI NAS:AKCA NAS:ARNA
Traded in other countries I4P.Germany
Address 10 Hudson Yards, 37th Floor, New York, NY, USA, 10011
Intercept Pharmaceuticals is a biotech company focused on developing and commercializing novel therapeutics to treat chronic liver diseases. Obeticholic acid, or OCA, is an agonist of the farnesoid X receptor. OCA was approved as Ocaliva for the treatment of primary biliary cirrhosis in 2016 and is being developed for a variety of chronic liver diseases, including nonalcoholic steatohepatitis. Intercept owns worldwide rights to OCA outside of China, where it has licensed out the product to Sumitomo Dainippon Pharma.

Ratios

Current vs industry vs history
PS Ratio 12.54
PS Ratio ranked lower than
59.78% of 726 companies
in the Biotechnology industry.
Industry Max: 113071.43, Med: 9999, Min: 0.01
ICPT: 12.54
Ranked among companies with meaningful PS Ratio only.
PS Ratio range over the past 10 years
Min: 10.38, Med: 325.67, Max: 5313.33
Current: 12.54
10.38
5313.33
EV-to-EBIT -9.54
EV-to-EBIT ranked lower than
100.00% of 261 companies
in the Biotechnology industry.
Industry Max: 4391.42, Med: 22.17, Min: 0.02
ICPT: -9.54
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: -155.6, Med: -10.8, Max: -3.8
Current: -9.54
-155.6
-3.8
EV-to-EBITDA -9.73
EV-to-EBITDA ranked lower than
100.00% of 281 companies
in the Biotechnology industry.
Industry Max: 28816.43, Med: 18.08, Min: 0.02
ICPT: -9.73
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: -156.3, Med: -10.8, Max: -3.9
Current: -9.73
-156.3
-3.9
EV-to-Revenue 13.96
EV-to-Revenue ranked lower than
57.20% of 771 companies
in the Biotechnology industry.
Industry Max: 118933, Med: 13.69, Min: 0.05
ICPT: 13.96
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: 10, Med: 287.9, Max: 5479.5
Current: 13.96
10
5479.5
Current Ratio 3.72
Current Ratio ranked higher than
63.50% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.46, Min: 0.01
ICPT: 3.72
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 0.48, Med: 8.62, Max: 31.15
Current: 3.72
0.48
31.15
Quick Ratio 3.72
Quick Ratio ranked higher than
64.06% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.18, Min: 0.01
ICPT: 3.72
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 0.48, Med: 8.62, Max: 31.15
Current: 3.72
0.48
31.15
Days Sales Outstanding 54.80
Days Sales Outstanding ranked higher than
68.26% of 668 companies
in the Biotechnology industry.
Industry Max: 1096.56, Med: 64.17, Min: 0.06
ICPT: 54.8
Ranked among companies with meaningful Days Sales Outstanding only.
Days Sales Outstanding range over the past 10 years
Min: 45.99, Med: 52.16, Max: 133.5
Current: 54.8
45.99
133.5
Days Payable 2.00
Days Payable ranked lower than
97.57% of 536 companies
in the Biotechnology industry.
Industry Max: 1651.36, Med: 63.91, Min: 0.12
ICPT: 2
Ranked among companies with meaningful Days Payable only.
Days Payable range over the past 10 years
Min: 2, Med: 1779.51, Max: 1854.29
Current: 2
2
1854.29

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -5.30
3-Year Share Buyback Rate ranked higher than
73.98% of 857 companies
in the Biotechnology industry.
Industry Max: 43.5, Med: -13.4, Min: -1815.4
ICPT: -5.3
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -86, Med: -11.2, Max: -5.3
Current: -5.3
-86
-5.3

Valuation & Return

Current vs industry vs history
Price-to-Median-PS-Value 0.04
Price-to-Median-PS-Value ranked higher than
97.79% of 678 companies
in the Biotechnology industry.
Industry Max: 126.94, Med: 0.92, Min: 0.01
ICPT: 0.04
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Price-to-Median-PS-Value range over the past 10 years
Min: 0.03, Med: 1.13, Max: 11.05
Current: 0.04
0.03
11.05
Earnings Yield (Joel Greenblatt) % -10.47
Earnings Yield (Greenblatt) ranked lower than
54.67% of 1081 companies
in the Biotechnology industry.
Industry Max: 5000, Med: -7.73, Min: -10000
ICPT: -10.47
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: -26, Med: -9.3, Max: -0.6
Current: -10.47
-26
-0.6

More Statistics

Revenue (TTM) (Mil) $ 196.09
EPS (TTM) $ -10.76
Beta 1.45
Volatility % 60.22
52-Week Range $ 73.01 - 133.74
Shares Outstanding (Mil) 32.55

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 2
Positive ROA N
Positive CFROA N
Higher ROA yoy N
CFROA > ROA Y
Lower Leverage yoy N
Higher Current Ratio yoy N
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy Y